Lords Mark Inds.
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Lords Mark Industries scheduled a board meeting for October 23, 2026 to consider raising a Rs 100 crore unsecured loan from promoter Sachidanand H Upadhyay, with an option to convert the loan into equity on mutually agreed terms subject to shareholder approval. It followed the promoter's sale of 1,93,55,581 shares in two September tranches for net proceeds of about Rs 163.6 crore, alongside a proposal to reinvest the majority into expansion of the medical device unit. Consolidated revenue was Rs 684.8 crore in the year to March 2026, with total borrowings of Rs 383.2 crore and goodwill of about Rs 255 crore. The company completed the Rs 4.5 crore acquisition of Radio Electric, a specialised transformer maker, on October 12.
Powered by Tijori
Lords Mark Industries scheduled a board meeting for October 23, 2026 to consider raising a Rs 100 crore unsecured loan from promoter Sachidanand H Upadhyay, with an option to convert the loan into equity on mutually agreed terms subject to shareholder approval. It followed the promoter's sale of 1,93,55,581 shares in two September tranches for net proceeds of about Rs 163.6 crore, alongside a proposal to reinvest the majority into expansion of the medical device unit. Consolidated revenue was Rs 684.8 crore in the year to March 2026, with total borrowings of Rs 383.2 crore and goodwill of about Rs 255 crore. The company completed the Rs 4.5 crore acquisition of Radio Electric, a specialised transformer maker, on October 12.
Powered by Tijori
Lords Mark Industries achieved 25% minimum public shareholding after promoter sales of 1,03,56,983 shares on 18 September and 89,98,598 shares on 29 September. The first tranche reduced the single-holder stake from 77.54% to 75.11%. The board approved an in-principle scheme on 6 August to reach 25% public holding through a promoter offer-for-sale and a public-only rights issue. Net proceeds of Rs87.39 crore were credited for the first tranche, with a proposal to reinvest the majority into medical device unit expansion. Consolidated revenue was Rs684.75 crore with profit after tax of Rs48.59 crore in the year to March.
Powered by Tijori
Lords Mark Industries achieved 25% minimum public shareholding after promoter sales of 1,03,56,983 shares on 18 September and 89,98,598 shares on 29 September. The first tranche reduced the single-holder stake from 77.54% to 75.11%. The board approved an in-principle scheme on 6 August to reach 25% public holding through a promoter offer-for-sale and a public-only rights issue. Net proceeds of Rs87.39 crore were credited for the first tranche, with a proposal to reinvest the majority into medical device unit expansion. Consolidated revenue was Rs684.75 crore with profit after tax of Rs48.59 crore in the year to March.
Powered by Tijori
Lords Mark Industries promoter Sachidanand H Upadhyay sold 10,356,983 equity shares, representing 2.43% of voting capital, through the open market on 18 September 2026. His holding fell to 320,439,246 shares, or 75.11%, from 330,796,229 shares, or 77.54%, with total equity capital unchanged at 42,66,22,217 shares of Rs 10 each. The board had approved an in-principle scheme in August to raise public shareholding to 25% through a promoter offer for sale and a rights issue subscribed by public shareholders. Consolidated revenue was Rs 684.75 crore with net profit of Rs 48.59 crore in the year to March, and Rs 307.7 crore with net profit of Rs 33.2 crore in the June quarter. The company's shares were listed on the BSE, with an application for NSE listing submitted in July.
Powered by Tijori
Lords Mark Industries promoter Sachidanand H Upadhyay sold 10,356,983 equity shares, representing 2.43% of voting capital, through the open market on 18 September 2026. His holding fell to 320,439,246 shares, or 75.11%, from 330,796,229 shares, or 77.54%, with total equity capital unchanged at 42,66,22,217 shares of Rs 10 each. The board had approved an in-principle scheme in August to raise public shareholding to 25% through a promoter offer for sale and a rights issue subscribed by public shareholders. Consolidated revenue was Rs 684.75 crore with net profit of Rs 48.59 crore in the year to March, and Rs 307.7 crore with net profit of Rs 33.2 crore in the June quarter. The company's shares were listed on the BSE, with an application for NSE listing submitted in July.
Powered by Tijori
Lords Mark Industries entered into a strategic collaboration with ARKALL Holdings Limited to establish and operate pathology laboratories and commercialise its medical devices, diagnostics and healthcare products across the Caribbean. The rollout was to start in Trinidad & Tobago and extend in phases across 28 markets over three years, with ARKALL funding 100% of the required investment and leading commercialisation. Lords Mark projected about US$100 million of export revenue between FY27 and FY31 and estimated the identified pathology and diagnostics opportunity at US$1.24 billion, subject to regulatory approvals and execution. Healthcare, including diagnostics, surgical products, IVD and dialysis, accounted for about 75% of the company's FY26 revenue.
Powered by Tijori
Lords Mark Industries entered into a strategic collaboration with ARKALL Holdings Limited to establish and operate pathology laboratories and commercialise its medical devices, diagnostics and healthcare products across the Caribbean. The rollout was to start in Trinidad & Tobago and extend in phases across 28 markets over three years, with ARKALL funding 100% of the required investment and leading commercialisation. Lords Mark projected about US$100 million of export revenue between FY27 and FY31 and estimated the identified pathology and diagnostics opportunity at US$1.24 billion, subject to regulatory approvals and execution. Healthcare, including diagnostics, surgical products, IVD and dialysis, accounted for about 75% of the company's FY26 revenue.
Powered by Tijori
Aug 24 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES LTD- ENTERED COLLABORATION WITH ARKALL HOLDINGS LTD FOR ESTABLISHING PATHOLOGY LABORATORIES
LORD'S MARK INDUSTRIES LTD- $100 MILLION EXPORT REVENUE PROJECTED BETWEEN FY27-FY31
Source text: ID:nBSE9rdGws
Further company coverage: LORS.BO
(([email protected];))
Aug 24 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES LTD- ENTERED COLLABORATION WITH ARKALL HOLDINGS LTD FOR ESTABLISHING PATHOLOGY LABORATORIES
LORD'S MARK INDUSTRIES LTD- $100 MILLION EXPORT REVENUE PROJECTED BETWEEN FY27-FY31
Source text: ID:nBSE9rdGws
Further company coverage: LORS.BO
(([email protected];))
Lord's Mark Industries set FY2027 consolidated revenue guidance of at least ₹1,550 crore and PAT of at least ₹178 crore, implying growth of more than 20% and 50%, respectively, over FY2026. It proposed demerging its renewable energy and LED division into Lords Shakti Power, retaining a 60% stake and distributing shares in the new entity to existing shareholders. It planned an exclusive India agreement for CAR-T therapy and treatment capability at five centres, with the first two targeted for Mumbai and Bengaluru by March 2027. It had established a UK subsidiary and was in the process of establishing a Swiss subsidiary to operate pathology laboratories supplied from its Indian manufacturing base, with an NHS approval application submitted for the UK operation. A new healthcare-delivery subsidiary was to begin with two approximately 70-bed oncology hospitals at Vapi and Solapur, supported by a proposed ₹200 crore debt raise, alongside a planned network of 50 dialysis centres. OneDNA patient trials were complete and the platform had received ICMR approval; the Biomescan platform had received its manufacturing licence on 10 August. Healthcare and diagnostics accounted for roughly 75% of FY26 revenue, while borrowings stood at ₹274 crore.
Powered by Tijori
Lord's Mark Industries set FY2027 consolidated revenue guidance of at least ₹1,550 crore and PAT of at least ₹178 crore, implying growth of more than 20% and 50%, respectively, over FY2026. It proposed demerging its renewable energy and LED division into Lords Shakti Power, retaining a 60% stake and distributing shares in the new entity to existing shareholders. It planned an exclusive India agreement for CAR-T therapy and treatment capability at five centres, with the first two targeted for Mumbai and Bengaluru by March 2027. It had established a UK subsidiary and was in the process of establishing a Swiss subsidiary to operate pathology laboratories supplied from its Indian manufacturing base, with an NHS approval application submitted for the UK operation. A new healthcare-delivery subsidiary was to begin with two approximately 70-bed oncology hospitals at Vapi and Solapur, supported by a proposed ₹200 crore debt raise, alongside a planned network of 50 dialysis centres. OneDNA patient trials were complete and the platform had received ICMR approval; the Biomescan platform had received its manufacturing licence on 10 August. Healthcare and diagnostics accounted for roughly 75% of FY26 revenue, while borrowings stood at ₹274 crore.
Powered by Tijori
Lord's Mark Industries received a manufacturing licence under India's Medical Devices Rules, 2017 for its Biomescan Analytics Platform, describing it as the country's first and only such licence for an IVD software product. The Software as a Medical Device combines whole-metagenome sequencing with a bioinformatics pipeline to produce gut-microbiome profiles, diversity scores, enterotype classifications and personalised dietary recommendations. The platform was licensed as a wellness and health-information tool for preventive healthcare and early health-risk assessment. Healthcare contributed about 75% of FY26 revenue, and the company commissioned a 14,000-square-foot IVD facility at Vasai in June.
Powered by Tijori
Lord's Mark Industries received a manufacturing licence under India's Medical Devices Rules, 2017 for its Biomescan Analytics Platform, describing it as the country's first and only such licence for an IVD software product. The Software as a Medical Device combines whole-metagenome sequencing with a bioinformatics pipeline to produce gut-microbiome profiles, diversity scores, enterotype classifications and personalised dietary recommendations. The platform was licensed as a wellness and health-information tool for preventive healthcare and early health-risk assessment. Healthcare contributed about 75% of FY26 revenue, and the company commissioned a 14,000-square-foot IVD facility at Vasai in June.
Powered by Tijori
Aug 10 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES - RECEIVES MANUFACTURING LICENCE FOR BIOMESCAN ANALYTICS PLATFORM
Source text: ID:nBSE1sb1sJ
Further company coverage: LORS.BO
(([email protected];))
Aug 10 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES - RECEIVES MANUFACTURING LICENCE FOR BIOMESCAN ANALYTICS PLATFORM
Source text: ID:nBSE1sb1sJ
Further company coverage: LORS.BO
(([email protected];))
Lord's Mark Industries' board approved in principle a two-step scheme to meet the 25% minimum public shareholding requirement, combining an offer for sale by the promoter group with a rights issue subscribed exclusively by public shareholders. It also constituted a dedicated MPS Committee and appointed Nuvama Wealth Management as advisor for the restructuring and related corporate actions. The company had approved a preferential allotment at ₹195 a share in late July. Its standalone FY26 fourth-quarter revenue was ₹442 crore and profit after tax was ₹41 crore.
Powered by Tijori
Lord's Mark Industries' board approved in principle a two-step scheme to meet the 25% minimum public shareholding requirement, combining an offer for sale by the promoter group with a rights issue subscribed exclusively by public shareholders. It also constituted a dedicated MPS Committee and appointed Nuvama Wealth Management as advisor for the restructuring and related corporate actions. The company had approved a preferential allotment at ₹195 a share in late July. Its standalone FY26 fourth-quarter revenue was ₹442 crore and profit after tax was ₹41 crore.
Powered by Tijori
July 20 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES LTD - ACHIEVES L1 STATUS FOR CONTRACT FROM CHHATTISGARH STATE RENEWABLE ENERGY DEVELOPMENT AGENCY
Source text: ID:nnAZN4T8RSX
Further company coverage: LORS.BO
(([email protected];))
July 20 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES LTD - ACHIEVES L1 STATUS FOR CONTRACT FROM CHHATTISGARH STATE RENEWABLE ENERGY DEVELOPMENT AGENCY
Source text: ID:nnAZN4T8RSX
Further company coverage: LORS.BO
(([email protected];))
Lord's Mark Industries Limited has commissioned a new 14,000-square-foot in-vitro diagnostics manufacturing unit at Vasai East in Maharashtra, two months ahead of its original August 2026 schedule. The facility expands the company's total operational manufacturing area from 20,000 square feet to 34,000 square feet. The plant will produce a portfolio of 56 ELISA test kits and a new range of rapid diagnostic test kits. The research and development wing has been dedicated to the memory of the late Ratan Tata and will focus on molecular biology and genetic science. The company also disclosed plans for a third facility, also at Vasai, dedicated to early cancer detection research and named after the late Dr. A.P.J. Abdul Kalam, with operations expected from January 2029, as well as a long-term vision to build one of the world's largest AI-enabled medical device manufacturing plants in India.
Powered by Tijori
Lord's Mark Industries Limited has commissioned a new 14,000-square-foot in-vitro diagnostics manufacturing unit at Vasai East in Maharashtra, two months ahead of its original August 2026 schedule. The facility expands the company's total operational manufacturing area from 20,000 square feet to 34,000 square feet. The plant will produce a portfolio of 56 ELISA test kits and a new range of rapid diagnostic test kits. The research and development wing has been dedicated to the memory of the late Ratan Tata and will focus on molecular biology and genetic science. The company also disclosed plans for a third facility, also at Vasai, dedicated to early cancer detection research and named after the late Dr. A.P.J. Abdul Kalam, with operations expected from January 2029, as well as a long-term vision to build one of the world's largest AI-enabled medical device manufacturing plants in India.
Powered by Tijori
June 23 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES - SETS UP 14,000 SQ FT IVD MANUFACTURING FACILITY AT VASAI, MAHARASHTRA
Source text: ID:nBSE2fl7LR
Further company coverage: LORS.BO
(([email protected];))
June 23 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES - SETS UP 14,000 SQ FT IVD MANUFACTURING FACILITY AT VASAI, MAHARASHTRA
Source text: ID:nBSE2fl7LR
Further company coverage: LORS.BO
(([email protected];))
Lords Mark Industries resolved a legal dispute with Bennett Coleman and Co. Ltd after the Delhi High Court dismissed a petition seeking interim relief over the conversion of five warrants. The company issued a communication confirming BCCL's entitlement to 10,28,483 equity shares at a conversion price of ₹158 per share under a share cum warrant subscription agreement dated August 1, 2023. The petition, filed under Section 9 of the Arbitration and Conciliation Act, was withdrawn after Lords Mark acknowledged the obligation and committed to issuing the shares within three days of the court's order. The development removes a key uncertainty ahead of the company's planned listing and commenced trading of its equity shares.
Powered by Tijori
Lords Mark Industries resolved a legal dispute with Bennett Coleman and Co. Ltd after the Delhi High Court dismissed a petition seeking interim relief over the conversion of five warrants. The company issued a communication confirming BCCL's entitlement to 10,28,483 equity shares at a conversion price of ₹158 per share under a share cum warrant subscription agreement dated August 1, 2023. The petition, filed under Section 9 of the Arbitration and Conciliation Act, was withdrawn after Lords Mark acknowledged the obligation and committed to issuing the shares within three days of the court's order. The development removes a key uncertainty ahead of the company's planned listing and commenced trading of its equity shares.
Powered by Tijori
March 10 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES - ENTERS TECHNOLOGY TRANSFER AGREEMENT WITH C-MET FOR BREAST CANCER DETECTION DEVICE
Source text: ID:nBSEb7XLV2
Further company coverage: LORS.BO
(([email protected];))
March 10 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES - ENTERS TECHNOLOGY TRANSFER AGREEMENT WITH C-MET FOR BREAST CANCER DETECTION DEVICE
Source text: ID:nBSEb7XLV2
Further company coverage: LORS.BO
(([email protected];))
Feb 16 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES LTD - SIGNING OF MOU FOR GREEN HYDROGEN PROJECTS
Source text: ID:nBSE8FBKpj
Further company coverage: LORS.BO
(([email protected];))
Feb 16 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
LORD'S MARK INDUSTRIES LTD - SIGNING OF MOU FOR GREEN HYDROGEN PROJECTS
Source text: ID:nBSE8FBKpj
Further company coverage: LORS.BO
(([email protected];))
Jan 13 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
SECURES NHAI MANDATE FOR SOLAR HIGHWAY LIGHTING
Source text: ID:nBSEbJFPhS
Further company coverage: LORS.BO
(([email protected];))
Jan 13 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
SECURES NHAI MANDATE FOR SOLAR HIGHWAY LIGHTING
Source text: ID:nBSEbJFPhS
Further company coverage: LORS.BO
(([email protected];))
Jan 6 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
APPROVAL TO RAISE 2 BILLION RUPEES VIA RIGHTS ISSUE
Source text: ID:nBSE24KQmf
Further company coverage: LORS.BO
(([email protected];))
Jan 6 (Reuters) - Lord's Mark Industries Ltd LORS.BO:
APPROVAL TO RAISE 2 BILLION RUPEES VIA RIGHTS ISSUE
Source text: ID:nBSE24KQmf
Further company coverage: LORS.BO
(([email protected];))
March 4 (Reuters) - Kratos Energy & Infrastructure Ltd KRAT.BO:
SEBI RELEASES ATTACHMENT OF KRATOS ENERGY BANK ACCOUNTS
Source text: ID:nBSEbG1R9G
Further company coverage: KRAT.BO
(([email protected];;))
March 4 (Reuters) - Kratos Energy & Infrastructure Ltd KRAT.BO:
SEBI RELEASES ATTACHMENT OF KRATOS ENERGY BANK ACCOUNTS
Source text: ID:nBSEbG1R9G
Further company coverage: KRAT.BO
(([email protected];;))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Lords Mark Inds. do?
Kratos Energy deals with machineries and provides power and energy sector consultation in India. It also offers financial services and is based in Mumbai.
Who are the competitors of Lords Mark Inds.?
Lords Mark Inds. major competitors are AYE Finance, Indostar Capital Fin, Ashika Global Sec., Sindhu Trade Links, Northern Arc Capital, SG Finserve, PTC India Fin. Serv. Market Cap of Lords Mark Inds. is ₹3,084 Crs. While the median market cap of its peers are ₹3,196 Crs.
Is Lords Mark Inds. financially stable compared to its competitors?
Lords Mark Inds. seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Lords Mark Inds. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Lords Mark Inds. latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How strong is Lords Mark Inds. balance sheet?
The companies balance sheet of Lords Mark Inds. is weak, but was strong historically.
Is the profitablity of Lords Mark Inds. improving?
Yes, profit is increasing. The profit of Lords Mark Inds. is ₹83.49 Crs for TTM, ₹48.59 Crs for Mar 2026 and -₹6.73 Crs for Mar 2025.
Is Lords Mark Inds. stock expensive?
Lords Mark Inds. is expensive when considering the PE ratio, however latest Price to Book is < 3 yr avg Price to Book. Latest PE of Lords Mark Inds. is 36.94 while 3 year average PE is 35.67. Also latest Price to Book of Lords Mark Inds. is 2.93 while 3yr average is 5.03.
Has the share price of Lords Mark Inds. grown faster than its competition?
Lords Mark Inds. has given better returns compared to its competitors. Lords Mark Inds. has grown at ~190.48% over the last 2yrs while peers have grown at a median rate of -10.0%
Is the promoter bullish about Lords Mark Inds.?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Lords Mark Inds. is 75.3% and last quarter promoter holding is 79.84%. Please check if dilutions happened via QIP/ Offerings etc.
Are mutual funds buying/selling Lords Mark Inds.?
There is Insufficient data to gauge this.